Trials / Terminated
TerminatedNCT05743036
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination With Encorafenib and Cetuximab in Adults With Metastatic Colorectal Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZN-c3 | ZN-c3 tablet by mouth, in combination with encorafenib |
| DRUG | Encorafenib | Encorafenib capsule by mouth, in combination with ZN-c3 |
| DRUG | Cetuximab | Infusion |
Timeline
- Start date
- 2023-02-27
- Primary completion
- 2024-07-16
- Completion
- 2025-07-09
- First posted
- 2023-02-24
- Last updated
- 2025-08-08
Locations
27 sites across 7 countries: United States, Australia, Germany, Hungary, Italy, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05743036. Inclusion in this directory is not an endorsement.